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The treatment of myomas using the technique of
magnetic resonance-guided focused ultrasound
(MRgFUS; syn.: HIFU = high-intensity focused ul-
trasound) represents a thermoablative procedure
by which the tissue to be treated is heated in
small volume steps by focused ultrasound under
continuous MR imaging control until complete
denaturation of the planned myoma volume has
been achieved (so-called sonifications, syn.: soni-
cations). After successful thermoablation control
scans reveal the absence of contrast medium up-
take in the treated tissue (correspondingly:
npv = non-perfused volume).
The MRgFUS procedure is organ-conserving, non-
invasive and can be performed in an outpatient
setting.
This treatment option is relatively new and is cur-
rently only available in a few specialised centres.
The objective of MRgFUS therapy is the reduction
or elimination of complaints caused by myomas
in the afflicted women. The ultrasound treatment
leads to a shrinking of the myoma. A complete re-
mission of the myoma is however not to be ex-
pected.
There is agreement between the specialties gy-
naecology and interventional radiology that an
indication for the required therapy in cases of
uterus myomatosus is only given after expert ex-
amination by and consultation with a gynaecolo-
gist. A complete and comprehensive consultation
on treatment options for symptomatic uterus
myomatosus explicitly includes, besides the drug
and surgical treatment options, also the non-sur-
gical treatment options such as uterine artery
embolisation (UAE) and MRgUS. The decision for
or against a therapeutic option should be made
in consideration of the individual patientʼs wishes
and with a full knowledge of alternative strat-
egies, their chances of success, their limitationsided Focused… Geburtsh Frauenheilk 2014; 74: 430–432as well as their typical side effects and possible
complications (informed consent).
In Germany, Austria and Switzerland, MRgFUS
constitutes a treatment option for women with
complaints due to myomas that enables a further
individualisation of the therapy for uterus myo-
matosus.Aim of the Consensus Meeting
!
The intention of this first consensus meeting was
to make an evaluation and classification of
MRgFUS in the therapeutic toolbox for myoma
treatment. The 13 participants of the radiology-
gynaecology expert meeting have, on the basis of
an assessment of the available literature and their
own experience, after extensive discussions,
reached a consensus between the two involved
specialties. The group of experts was fully aware
that the possibilities and limitations of a radiolog-
ical therapy option would have to be discussed
with experts from the field of gynaecology who
do not perform such procedures themselves but
who have extensive expertise and experience in
the diagnosis as well as drug and surgical treat-
ment of diseases of the female genital organs.
The expert group comprising 8 radiologists and 5
gynaecologists that came together on January 19,
2013 in Berlin for the first radiology-gynaecology
consensus meeting on MRgFUS therapy also in-
cluded radiologists and gynaecologists from Swit-
zerland and Austria.
After extensive and, in part, controversial discus-
sion the group formulated in consensus the fol-
lowing recommendations. The consensus paper
was supported by the gynaecologist and radiolo-
gists listed at the end of the present contribution.
This paper reflects the current state of knowl-
edge.
431StatementStructural Prerequisites for the Performance
of MRgFUS Therapy
!
MRgFUS therapy should only be carried out in hospitals in which
specialists with expertise and experience in the performance of
MRgFUS therapy are available. This should also include the con-
servative and, if necessary, surgical management of side effects
and complications. Furthermore, facilities for initiation of a post-
interventional pain therapy should be at hand.Examinations Necessary Prior to MRgFUS Therapy
!
Fundamental for therapeutic decision making is a gynaecological
examination including vaginal and/or abdominal ultrasound (de-
pending on the size of the uterus myomatosus) by a specialist. An
essential prerequisite is the performance of MR imaging with
contrast medium (CM), if at all possible in a prone position since
MRI is the only procedure that enables an adequate visualisation
of the surrounding organs, especially intestinal loops. Imaging
with CM also allows one to estimate if and towhat extent themy-
oma is perfused.
Prior to each and every MRgFUS treatment, the indications for
hysteroscopy and fractionated abrasion in dependence on the
bleeding pattern as well as the density and structure of the endo-
metrium should be checked critically. Also in the past year at the
most there should have been an unremarkable cytological smear
test of the cervix uteri.Indications for MRgFUS Therapy
!
Indication for an MRgFUS treatment is a symptomatic uterus my-
omatosus.
Prerequisite is a uterus myomatosus in which the anatomic posi-
tion of the myomas allows a safe access for the MRgFUS. A total of
more than 5 myomas makes the procedure more difficult. For
myomas with a diameter of more than 10 cm the indication for
MRgFUS therapy is also more critical due to the large myoma vol-
ume and the associated long treatment times.
MRgFUS represents an alternative to surgical and drug treatment
as well as to UAE. Foundations for the therapeutic decision mak-
ing are the objective of the treatment and the individual patientʼs
wishes. When the facilities for its performance are available,
MRgFUS represents a good option for patients wishing for the
least invasive treatment possible.Criteria for Success of MRgFUS Therapy
!
The main issues for therapeutic success after MRgFUS treatment
are an improvement or complete elimination of the complaints
due to myoma. A reduction in volume of the myoma is also tar-
geted but rather as a secondary therapeutic aim.Beck A et al. MContraindications for MRgFUS Therapy
!
" suspected malignancy (absolute)
" pregnancy (absolute)
" acute inflammatory process (absolute)
" uterus myomatosus with more than 5 myomas (relative, indi-
vidual decision)
" uterine myoma with a diameter of over 10 cm (relative)
" no adequate acoustic window possible for treatment (e.g.:
overlapping intestines, large scars in the acoustic window, very
dorsal position of myoma) (relative)
" subserous pedunculated myoma (relative)
" myoma positioned in the posterior wall or, respectively, near
the os sacrum (relative)
" general contraindications with regard to MR contrast media
(relative)
" relative and absolute contradictions with regard to MRIMRgFUS Therapy in Patients with a Desire
to Have Children
!
Currently available case reports show that a pregnancy after
MRgFUS is possible and can be brought to a successful conclusion,
however the data are insufficient for a definitive recommenda-
tion.Side Effects/Complications of MRgFUS Therapy
!
Relevant side effects and complications after performance of
MRgFUS treatment are rare:
" pain during the treatment (mostly mild and of short duration)
" (slight) burning of the skin
" mild inflammation of the subcutaneous fat and musculature of
the abdominal wall
" paraesthesia of the legs due to nerve irritation or injury
" deep leg vein thrombosis (very rare)
" intestinal perforation (extremely rare)
After therapy the vaginal discharge of tissue particles is possible.
Heavy and/or irregular periods may occur for up to about 3
months after treatment.Follow-up Examination after MRgFUS Therapy
!
When the complaints decline, a follow-up examination by a spe-
cialist (e.g., ultrasound) is recommended at about 6 months after
MRgFUS. If the complaints persist and/or complications the fol-
low-up examination should be made earlier, a generous indica-
tion for an MRI control is then given. Histological clarification is
needed in the case of conspicuous imaging findings.Perspectives
!
It is planned in about 2 years under consideration of the data that
will then available and the gained experience to again reconsider
and revise these recommendations on MRgFUS therapy.agnetic Resonance-Guided Focused… Geburtsh Frauenheilk 2014; 74: 430–432
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